ORLANDO, Fla.--(BUSINESS WIRE)--NantHealth, Inc. (NASDAQ-GS: NH), a next-generation, evidence-based, personalized healthcare company, announced today that Patrick Soon-Shiong, MD, has been chosen to keynote at the Intelligent Health™ Pavilion during the HIMSS 2017 Annual Conference & Exhibition in Orlando, Florida. Dr. Soon-Shiong will introduce the NantDaVinci Cancer Engine, an augmented intelligence processor integrated into a secure terabit per second fiber network that rapidly analyzes genomes within a patient’s cancer tumor. The keynote will take place on Monday, February 20, at 10:30 a.m. ET at booth 8361.
The presentation, “Unlocking the Code with the NantDaVinci Cancer Engine” will unveil how NantHealth has been leveraging advancements in supercomputing, augmented intelligence, machine vision, machine learning and natural language processing to identify and read the unique biological signature inside each cancer tumor and how that code can be unlocked to create a truly personalized treatment and a cancer vaccine.
To date, the NantDaVinci Supercomputing Engine has successfully completed analyses of more than 21,000 cancer tissue samples analyzed for whole genome, whole exome and RNA from more than 7,000 unique patients with multiple tumor types—and with the world's largest database of human cancer whole genomes— has enabled the discovery of novel neoepitopes in cancer tissue for the development of neoepitope antibodies and vaccines in the war against cancer. Over 100 seminal patents have been issued covering this integrated augmented, amplified and adaptive intelligence platform.
The session will also be available for viewing via Facebook Live at www.Facebook.com/NantHealth.
|
WHAT: |
Unlocking the Code with the NantDaVinci Cancer Engine |
||
|
WHO: |
Patrick Soon-Shiong, MD, founder and CEO, NantHealth | ||
|
WHEN: |
Monday, February 20, 2017 at 10:30 a.m. - 11:30 a.m. EST | ||
|
WHERE: |
HIMSS Annual Conference & Exhibition | ||
| Intelligent Health Pavilion, Booth 8361 | |||
| Orange County Convention Center | |||
| Orlando, Florida | |||
|
MEDIA |
|||
|
CONTACT: |
Jen Hodson | ||
| NantHealth | |||
| 310-853-7802 | |||
Cautionary Note Concerning Forward-Looking Statements
This
press release contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995, including, among
others, statements regarding the capabilities and anticipated utility of
our GPS Cancer, including predicting patient response and resistance to
therapeutics, enabling diagnoses by physicians and accelerating efforts
to bring novel combinations of therapeutic agents to cancer patients.
Forward-looking statements are subject to numerous risks and
uncertainties that could cause actual results to differ materially from
currently anticipated results. Factors that may cause future results to
differ materially from management’s current expectations include, among
other things, that GPS Cancer may not perform as anticipated, that
sufficient physicians may not adopt GPS Cancer to assist their diagnoses
or that healthcare payers may not provide reimbursement for GPS Cancer
as expected. Our business is subject to numerous additional risks and
uncertainties, including, among others, risks relating to market
acceptance of our products; our ability to successfully launch new
products and applications; competition; our sales, marketing and
distribution capabilities; our planned sales, marketing, and research
and development activities; unanticipated increases in costs or
expenses; and risks associated with international operations.
Information on these and additional risks, uncertainties, and other
information affecting our business and operating results can be found in
our existing and future filings with the Securities and Exchange
Commission. These forward-looking statements speak only as of the date
hereof. We disclaim any obligation to update these forward-looking
statements except as may be required by law.
About NantHealth, Inc.
NantHealth, Inc., a member of the
NantWorks ecosystem of companies, is a next-generation, evidence-based,
personalized healthcare company enabling improved patient outcomes and
more effective treatment decisions for critical illnesses. NantHealth’s
unique systems-based approach to personalized healthcare applies novel
diagnostics tailored to the specific molecular profiles of patient
tissues and integrates this molecular data in a clinical setting with
large-scale, real-time biometric signal and phenotypic data to track
patient outcomes and deliver precision medicine. For nearly a decade,
NantHealth has developed an adaptive learning system, CLINICS, which
includes its unique software, middleware and hardware systems
infrastructure that collects, indexes, analyzes and interprets billions
of molecular, clinical, operational and financial data points derived
from novel and traditional sources, continuously improves
decision-making and further optimizes our clinical pathways and decision
algorithms over time. For more information please visit www.nanthealth.com and
follow Dr. Soon-Shiong on Twitter @DrPatSoonShiong.
